Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05623488 · ClinicalTrials.gov registry record · Phase 1
CAR T Cells in Mesothelin-Expressing Breast Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05623488: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT05623488 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05623488, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Phase 1 - Safety and Proof of Concept
Interventions
- DRUG huCART-meso cells
- DEVICE Mesothelin Expression Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2025-04-07 |
| Phase | Phase 1 |
Why NCT05623488 stopped before completion
NCT05623488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which huCART-meso cells is the first listed.
NCT05623488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05623488 about?
NCT05623488 is a clinical study titled "CAR T Cells in Mesothelin-Expressing Breast Cancer". Phase 1 - Safety and Proof of Concept
What is the current status of trial NCT05623488?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-02-06. Estimated completion is 2025-04-07.
What interventions are being tested in trial NCT05623488?
The interventions under investigation include: huCART-meso cells (DRUG), Mesothelin Expression Testing (DEVICE).
Who is sponsoring clinical trial NCT05623488?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05623488's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI